Elevance Health(US:ELV) 智通财经网·2025-08-08 08:05Core Viewpoint - UBS reiterated a "Buy" rating for Elevance Health (ELV.US) with a target price of $435, indicating a potential upside of nearly 53% from the recent closing price of $283.48 [1] Financial Performance - Elevance Health reported Q2 revenue of $49.8 billion, exceeding market expectations [1] - Adjusted earnings per share (EPS) for Q2 were $8.84, in line with market expectations [1] - The company lowered its full-year EPS forecast by $4.50, equating to a pre-tax profit reduction of $1.3 billion [1] Future Projections - Elevance Health raised its 2025 medical loss ratio forecast by 90 basis points [1] - The increase in medical loss ratio expectations is attributed to unfavorable cost trends in the Affordable Care Act (ACA) transactions and Medicaid business [1] Investment Rationale - UBS maintains a "Buy" rating due to the potential profitability stability and growth opportunities in the commercial insurance and Carelon business segments, despite the raised medical loss ratio expectations [1]